Reverse Phase High Performance Liquid Chromatography Method for Simultaneous Estimation of Budesonide and Formoterol in Pure and Tablet

 

M. Venkata Ramana1*, Podishetty Akhila2, Salla Pujitha3, Akula Ganesh4, Yerolla Soundarya5

1Principal, Department of Chemistry, Surabhi Dayakar Rao College of Pharmacy, JNTUH, Telangana, India.

2Student, Department of Pharmaceutical Analysis,

Surabhi Dayakar Rao College of Pharmacy, JNTUH, Telangana, India.

3Assistant Professor, Department of Pharmacology,

Surabhi Dayakar Rao College of Pharmacy, JNTUH, Telangana, India.

4Associate Professor, Department of Chemistry,

Surabhi Dayakar Rao College of Pharmacy, JNTUH, Telangana, India.

5Assistant Professor, Department of Pharmaceutical Analysis,

Surabhi Dayakar Rao College of Pharmacy, JNTUH, Telangana, India.

*Corresponding Author E-mail:

 

ABSTRACT:

A simple, rapid and reliable reverse phase high-performance liquid chromatography (RP-HPLC) method was developed and validated for the simultaneous estimation of Budesonide and Formetrol in both pure drug substance and tablet dosage forms. Chromatographic separation was achieved using X-Bridge C18 column (4.6 × 150 mm, 5 μm) maintained at ambient temperature, with a mobile phase consisting of Methanol and Water in the ratio of 35:65 (v/v). The flow rate was set at 1.0 mL/min, and the detection was carried out using a UV detector at 235 nm. A 10 µL injection volume and a total run time of 8 minutes allowed efficient and rapid separation of both analytes. This developed method exhibited good resolution, satisfactory peak symmetry and high reproducibility. The parameters were evaluated according to ICH guidelines, the parameters such as linearity, accuracy, precision, specificity, robustness and system suitability. The validated results were found to be within acceptable limits. The validated RP-HPLC method is suitable for quality control analysis of Budesonide & Formoterol in pharmaceutical dosage forms.

 

KEYWORDS: RP-HPLC, Budesonide, Formoterol, X-Bridge C18 column, simultaneous estimation, validation.

 

 

 

INTRODUCTION:

Analytical chemistry plays a vital role in maintaining the quality of drugs. It consists of Qualitative and Quantitative estimations Method development involves considerable effort and time.1 RP-HPLC method with high sensitivity and selectivity will be very useful for the estimation pharmaceutical formulations.2 UV-spectrophotometric method and one HPTLC method is available for simultaneous estimation of these combinations.  The reported procedures are time consuming, expensive and relatively complicated.3 If no specific methods are available, new methods are developed to test the product of the novel. In order to investigate the existence of novel pharmaceutical or non-pharmaceutical product approaches they are being developed to reduce the amount without time for high accuracy and strength.4 In recent years many analytical techniques have been developed and utilize of a procedure to solve a problem.  Some HPLC methods had been developed for determination of these drugs individually or in combination with other drugs10-13 but No HPLC method for simultaneous estimation of these four drugs using monolithic silica columns has been reported till date.5

 

Budesonide with chemical name 11β, 21-Dihydroxy-16α, 17α-[butane-1,1-diylbis(oxy)] pregna-1,4-diene-3,20-dione is a glucocorticoid used in the management of asthma, the treatment of various skin disorders, and allergic rhinitis. Budesonide is provided as a mixture of two epimers of 22R and 22S. The 22R form is two times more active than the 22S epimer.6 The inhaled form is generally safe in pregnancy, but it is contraindicated as a primary treatment of status asthmaticus or other acute episode of asthma.7 Different analytical methods such as LC-MSMS, UFLC and HPLC and techniques were published for the estimation of Budesonide.8

 

Formoterol, ((RR)-(±)-N- [2-hydroxy-5- [1-hydroxy-2- [[2-(4- methoxyphenyl)-1 methylethyl] amino] ethyl] phenyl] formamide) is classified as a long-acting ß2 adrenergic agonist that is taken through inhalation. Because of its extended duration of action, it is not suitable for alleviating sudden asthma episodes. The application of formoterol is relevant in the treatment of asthma, COPD bronchospasm, and the prevention of exercise-induced bronchospasm.8,9,10

 

Now a day reversed-phase chromatography is the most commonly used separation technique in HPLC due to its broad application range. It is estimated that over 65% (possibly up to 90%) of all HPLC separations are carried out in the reversed phase mode11. The reasons for this include the simplicity, versatility and scope of the reversed-phase method as it is able to handle compounds of a diverse polarity and molecular mass.

 

The aim of the present study accordingly was to develop RP-HPLC method for anthraquinone marker and validate it as per ICH guideline.

 

 

Fig-1. Strucuture of Budesonide

 

Fig-2.  Structure of Formoterol

 

Experimental Methods:

Cоlumn: Hypersil C18 (4.6mm×250mm) 5µ particle size

Cоlumn temperаture: 30ŗC

Wavelength              : 252nm

Mobile phаse rаtiо   : Acetonitrile: Water (60:40% v/v)

Flоw rаte                    : 1.0ml/min

Injectiоn volume      : 10.00µl

Run time                    : 10 Minutes

 

Preparation of Mobile Phase:

Accurately measured 350ml (35%) of Methanol and 650ml of Water (65%) were mixed and degassed in a digital ultra sonicater for 10minutes and then filtered through 0.45µ filter under vacuum filtration.

 

Standard Solution Preparations:

Accurately weigh and transfer 10mg of Budesonide and Formoterol working standard into a 10ml of clean dry volumetric flasks add about 7ml of Methanol and sonicate to dissolve and removal of air completely and make volume up to the mark with the same Methanol. Further pipette 2.25ml of the above Budesonide and 0.45ml of the Formoterol stock solutions into a 10ml volumetric flask and dilute up to the mark with Methanol.

 

Validation Parameters:

Specificity Study of Drug:

Preparation of Sample Solution:

Take average weight of the Tablet and crush in a mortar by using pestle and weight 10mg equivalent weight of Budesonideand Formoterol sample into a 10mL clean dry volumetric flask and add about 7mL of Diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent. Further pipette 2.25ml of Budesonideand Formoterol above stock solution into a 10ml volumetric flask and dilute up to the mark with diluent.

 

Preparation of Drug Solutions for Linearity:

Accurately weigh and transfer 10mg of Budesonideand Formoterol working standard into a 10ml of clean dry volumetric flasks add about 7ml of Diluents and sonicate to dissolve it completely, make the volume up to the mark with the solvent. Injected the three replicate injections of standard and sample solutions and the assay was calculateds by using formula.

Preparation of Budesonideand Formoterol Product Solution for Precision:

Accurately weigh and transfer 10mg of Budesonideand Formoterolworking standard into a 10ml of clean dry volumetric flasks add about 7ml of Diluents and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution). Intermediate Precision/Ruggedness performed using the prescribed conditions and results shown in table-3.

 

Accuracy:

Preparation of 50%, 100% Standard Solutions:

Accurately weigh and transfer 10mg of Budesonideand Formoterolworking standard into a 10ml of clean dry volumetric flasks add about 7mL of Diluents and sonicate to dissolve it completely and make up to the volume to the mark with the same solvent. (Stock solution) Further pipette 1.12ml, 2.25ml of the above Budesonideand 0.225ml, 0.45ml of the Formoterol stock solutions into a 10ml volumetric flask and dilute up to the mark with Diluent.

 

RESULTS АND DISCUSSIОN:

 

Fig.3- Blank chromatogram fоr Trаil

 

 

Table-1: Chromatographic Data for Linearity Study

Drug

Cоncentratiоn mg/ml

Аverаge   Peаk Аreа

Budesonide

0

0

10

292985

20

430752

30

565265

40

693487

50

821584

Formoterol

0

0

15

2828756

30

5485784

45

7999859

60

10656542

75

13085985

 

 

Fig.4- Calibration curve of budesonide

 

 

Fig.5- Calibration Curve of Formoterol

 

 

Table-2. Peak results of Repeatability

Drug

Retention time

Аreа (µV*sec)

Height(µV)

USP Plаte Cоunt

USP Tаiling

 

Budesonide

1.792

548698

7458

7569

1.10

Mean

548568.2

Std.dev

1202.217

%RSD

0.2191554

1.791

548955

7485

7546

1.10

1.790

548745

7469

7592

1.09

1.790

549856

7463

7519

1.10

1.789

546587

7495

7535

1.09

Formoterol

3.435

7768958

43659

8659

1.12

Mean

7775152

Std.dev

9539.236

%RSD

0.122689

3.428

7765984

43856

8647

1.13

3.419

7785469

43658

8675

1.12

3.414

7785498

43549

8652

1.12

3.408

7769852

44526

8692

1.13

 

Table-3. Peak results of Intermediate precision

Concentration of drug (%)

Drug

Аreа

Аmоunt Added (ppm)

Аmоunt Fоund (ppm)

% Recovery

Mean Recovery

50%

Budesonide

286080.7

10.035

10

100.350%

100.291%

Formoterol

408328

15

15.074

100.493%

100.163%

100%

Budesonide

561215

20.100

20

100.500%

100.291%

Formoterol

798306.3

30

30.003

100.010%

100.163%

150%

Budesonide

833959.7

30.077

30

100.023%

100.291%

Formoterol

1189915

45

44.994

99.986%

100.163%

 

 

Table 4. Results of Accuracy for concentration 50%, 100%, 150%

Drug

Parameter used for sample analysis

Peak Area

Retention Time

Theoretical plates

Tailing factor

Budesonide

Аctuаl Flоw rаte оf 0.9mL/min

545265

1.794

7564

1.09

Less Flоw rаte оf 0.8mL/min

625486

1.867

7856

1.13

Mоre Flоw rаte оf 1.0mL/min

Mоre Flоw rаte оf 0.9mL/min

526548

1.744

7425

1.12

Less оrgаnic phаse

(аbоut 5 % decrease in оrgаnic phаse)

536548

1.831

7265

1.06

Mоre оrgаnic phаse

(аbоut 5 % Increase in оrgаnic phаse)

514875

1.874

7169

1.08

Formoterol

Аctuаl Flоw rаte оf 0.9mL/min

7768545

3.440

8695

1.12

Less Flоw rаte of 0.8mL/min

7985695

3.721

8948

1.13

Mоre Flоw rаte оf 1.0mL/min

7458642

3.097

8452

1.12

Less оrgаnic phаse

(аbоut 5 % decrease in оrgаnic phаse)

7685421

6.242

8365

1.10

Mоre оrgаnic phаse

(аbоut 5 % Increase in оrgаnic phаse)

7569864

2.402

8254

1.09

 

Table-5. Robustness results of Budesonide, Formeterol

Drug

Day

Name

Rt

Аreа (µV*sec)

Height

USP plate count

USP Tailing

 

Budesonide

Day1

Inj-1

1.787

556985

75986

7695

1.11

Mean area:

557827

Std. Dev

832.1803

% RSD

0.149183

Inj-2

1.789

558649

75986

7642

1.12

Inj-3

1.789

557847

75689

7683

1.12

Formoterol

Day1

Inj-1

3.482

7856982

44586

8758

1.13

Mean area:

7852300

Std. Dev

6187.659

% RSD

0.078801

Inj-2

3.477

7845285

44758

8769

1.14

Inj-3

3.477

7854633

44986

8728

1.13

Budesonide

Day2

Inj-1

1.790

536598

7365

7459

1.08

Mean area:

535390.3

Std. Dev

1049.608

% RSD

0.196045

Inj-2

1.789

534875

7358

7436

1.07

Inj-3

1.793

534698

7349

7482

1.08

Formoterol

Day2

Inj-1

3.474

7698521

42568

8582

1.11

Mean area:

7676801

Std. Dev

27487.83

% RSD

0.358064

Inj-2

3.473

7685985

42698

8546

1.10

Inj-3

3.478

7645897

42365

8574

1.10

 

Results of limit Detection:

Budesonide = 0.86µg/ml, Formoterol = 1.28µg/ml

 

Results of Quantitation Limit:

Budesonide = 2.58µg/ml, Formoterol = 3.84µg/ml

 

CONCLUSION:

RP-HPLC method showed valuable resolution between the peaks of Budesonide and Formoterol, with acceptable system suitability parameters including retion time, peak symmetry and theoretical plates. RP-HPLC method demonstrated effective and reproducible separation of Budesonide and Formoterol with sharp and well-defined peaks. These optimized chromatographic conditions ensure efficient separation is simple, accurate and providing good resolution with short rminute analysis time and suitable for routine quality control and pharmaceutical analysis of pure and tablet formulations.

 

REFERENCES:

1.      K. Umadevi, Mohibul Hoque, Ramya Sri. S. Quantitative Estimation of Roxithromycin and Ambroxol in Bulk and Tablet Dosage Forms by RP-HPLC Method. Research Journal of Science and Technology. 2023; 15(1): 1-7. doi: 10.52711/2349-2988.2023.00001L.

2.      Satyanarayana et. al. The Estimation of Raltigravir in Tablet dosage form by RP-HPLC.   2011; 1(3).

3.      R Siva Kumar, MR Santhanakrishnan, P Kumar Nallasivan, R Venkatanarayanan. Simultaneous RP-HPLC Method for Estimation of Ezetimibe and Simvastatin in Bulk and Dosage Forms. Research J. Pharm. and Tech. 2008;1(3): 211-214.

4.      Vishakha Shingote, S. D. Mankar, S. B. Dighe. A Review Article on Analytical Methods Development and Validation. Research Journal of Science and Technology. 2022; 14(1): 77-3. doi: 10.52711/2349-2988.2022.00012

5.      Mahmoud M. Sebaiy, Abdullah A. El-Shanawany, Sobhy M. El-Adl, Lobna M. Abdel-Aziz, Hisham A. Hashem. Rapid RP-HPLC Method for Simultaneous Estimation of Sparfloxacin, Gatifloxacin, Metronidazole and Tinidazole. Asian J. Pharm. Res. 2011; 1(4): 119-125.

6.      Anuja Kolsure, Kratika Daniel, Mahesh Bhat. Analytical methods for estimation of Budesonide in bulk and in pharmaceutical dosage forms: A Review. Research Journal of Pharmacy and Technology. 2021; 14(5): 2873-7. doi: 10.52711/0974-360X.2021.00505

7.      Avuthu Sai Sheela, Mukthinuthalapati Mathrusri Annapurna, Rangisetty Spandana Yasaswini. New validated stability indicating RP-UFLC method for the determination of Budesonide. Research J. Pharm. and Tech. 2020; 13(6): 2819-2824. doi: 10.5958/0974-360X.2020.00502.8

8.      Bandaru Sai Pavan Kumar, Mukthinuthalapati Mathrusri Annapurna. Development and validation of a new stability indicating RP-HPLC method for the quantification of Budesonide in pharmaceutical dosage forms in presence of an internal standard. Research Journal of Pharmacy and Technology. 2022; 15(5): 2103-9. doi: 10.52711/0974-360X.2022.00349

9.      Sivagami B, Bhaskar M, Pavan Kumar V, Meena D, Satheesh Kumar G, Chandrasekar R. Simultaneous Quantification of Mometasone Furoate and Formoterol Fumarate in Bulk and Formulations by RP-HPLC Method. Asian Journal of Pharmaceutical Analysis. 2023; 13(4): 267-2. doi: 10.52711/2231-5675.2023.00044

10.   Nidhi K. Patel, Shailesh K. Koradia. Development and Validation of stability indicating RP-HPLC method for the simultaneous estimation of Beclomethasone dipropionate and Formoterol fumarate in their combined pharmaceutical dosage form. Asian J. Pharm. Ana. 2016; 6(2): 83-90. doi: 10.5958/2231-5675.2016.00013.2

11.   Khodke AS, Potale LV, Patole SM, Damle MC. A Validated RP-HPLC Method Development for Determination of Anthraquinone Marker from the Roots of Rubia cordifolia Linn. Research J. Pharm. and Tech. 2011; 4(2): 326-328.

 

 

 

Received on 09.02.2026      Revised on 12.03.2026

Accepted on 06.04.2026      Published on 16.04.2026

Available online from April 18, 2026

Asian Journal of Pharmaceutical Analysis. 2026; 16(2):89-93.

DOI: 10.52711/2231-5675.2026.00012

©Asian Pharma Press All Right Reserved

 

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.